Mode
Text Size
Log in / Sign up
N/A N=57

The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

Enrolled (actual)
57
Serious AEs
90.2%
Results posted
Apr 2026
Primary outcome: Primary: Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression — 8.3 months

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
EUS FNA (endoscopic ultrasound fine needle aspiration) (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Carol Davila University of Medicine and Pharmacy
Primary completion
Sep 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression
8.3

Summary

Pancreatic adenocarcinoma still represents one of the "hot-topics" worldwide. Endoscopic ultrasonography was a breakthrough, bringing us closer to personalized treatment by getting histopathological samples through fine-needle-aspiration or fine-needle-biopsy. These samples can be analyzed and offer the possibility to detect a micro-RNA profile. Micro-RNAs are small non-coding RNA molecules that interfere in genic expression. Many studies focused on seric microRNA profile, though there are many implications in tissue micro-RNA profile, thus overexpression or under expression of these molecules might help us not only understand different cellular processes, but also interfere in personalized medicine in the future. The investigators propose a prospective, multicenter, randomized, cohort study on 60 patients with solid pancreatic masses to evaluate tissue microRNA profile obtained by EUS-FNA. The primary hypothesis is to correlate the microRNA tissular expression in pancreatic adenocarcinoma with tumor aggressive behavior, survival and response to treatment. The samples will be obtained from the participants during endoscopic ultrasonography, through fine needle aspiration, after consent was given to be a part of the study prior to the intervention. The probe will be preserved in a special recipient that stabilizes RNA and inhibits RNA-lazes, thus preventing RNA degradation by endogenous ribonucleases. The analysis of miRNA profile will be made using qRT-PCR array method, by miScript II RT Kit, miScript SYBR Green PCR Kit și miScript miRNA PCR Array Human Cancer Pathway Finder (MIHS-102Z) (Qiagen, GmbH). Thus a kit containing a number of 84 miRNAs will be analysed in every participant.

Eligibility Criteria

Inclusion Criteria

  • Pancreatic solid mass, with or without a cystic component
  • Age over 18 years old
  • Signed informed consent

Exclusion Criteria

  • Cystic pancreatic mass with no solid component
  • Abnormal coagulation (elevated INR >1.5, thrombocytopenia 42 seconds), participant on anticoagulant treatment that cannot stop the treatment
  • European Cooperative Oncology Group status 4
  • Pregnancy
  • Age under 18 years old
  • The participant does not want to sign the consent form, or is unable to
  • Difficult puncture position during endoscopic ultrasonography: vessels or Wirsung duct positioned in front of the needle (decision of the endoscopist)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04765410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search